September 11, 2019
TRiNDS is a neuromuscular and rare disease contract research organization (CRO). That means that our staffing, processes, and systems are designed with the unique needs of people with neuromuscular disorders and other rare diseases in mind.
We know rare and orphan disease clinical trials face different struggles than those about more common diagnoses. It’s harder to find eligible participants, the clinical care is more complex, the timelines are tighter, and the outcome measures are harder to execute.
All of us at TRiNDS come to work every day dedicated to making the best possible rare disease and neuromuscular clinical trials for people around the world. Whether it’s making clean datasets, hitting project management milestones, or running quality control checks on the eTMF – everyone works with our population in mind.
Our company was created in response to the needs of the neuromuscular and Duchenne muscular dystrophy (DMD) community. As Duchenne Awareness Month activities begin, it’s a time to reflect on where we’ve come from and where we’re going. The world of DMD drug development has rapidly changed the options for families everywhere. In other ways, DMD and neuromuscular drug development is just getting started – everyone will need to work together and stay focused in the months and years to come.
TRiNDS is a rare disease and neuromuscular CRO focused on executing high quality clinical trials in partnership with the community and innovative sponsors. As a specialty CRO, we help our clients to manage the unique needs of rare disease patients to complete clinical trials on time and on budget. Our rare disease focus and neuromuscular origins helps us to provide expert services for clinical operation, data management, and more. TRiNDS is currently accepting new clients developing products for rare disease, orphan disease, and neuromuscular patient populations. Contact TRiNDS today to request a quote.
